Business UpdateJun 5, 2026, 08:30 AM
Moleculin Annamycin shows high physician interest, payer support
AI Summary
Moleculin Biotech announced positive results from an independent market landscape assessment for Annamycin in relapsed/refractory acute myeloid leukemia (R/R AML). Oncologists reported a high likelihood-to-prescribe score of 6 out of 7, citing deep remissions, potential to bridge to transplant, biomarker-agnostic use, and reduced cardiotoxicity. Payers also showed strong support, viewing Annamycin as a meaningful value proposition due to its efficacy, safety, and broad applicability.
Key Highlights
- Oncologists reported an average likelihood-to-prescribe Annamycin of 6 out of 7.
- Physicians expressed strong interest in Annamycin's reported complete remission and MRD-negative remission profile.
- Annamycin's potential to bridge patients to bone marrow transplant was viewed as a meaningful clinical advantage.
- Biomarker-agnostic applicability was highly relevant given limitations of mutation-targeted therapies.
- Reduced cardiotoxicity was identified as an important differentiator, allowing for repeat dosing.
- Pediatric AML specialists viewed reduced cardiotoxicity as especially meaningful for long-term survivorship.
- Payers indicated Annamycin's efficacy, safety, and broad applicability support a compelling value proposition.
Price Impact
More from MBRX